Methoxyetomidate

Methoxyetomidate

Clinical data
Other names	ET-26
Identifiers
IUPAC name 2-methoxyethyl (R)-1-(1-phenylethyl)-1H-imidazole-5-carboxylate
CAS Number	1567838-90-7
PubChem CID	74766803
Chemical and physical data
Formula	C15H18N2O3
Molar mass	274.320 g·mol−1
3D model (JSmol)	Interactive image
SMILES [C@H](C)(N1C(C(OCCOC)=O)=CN=C1)C2=CC=CC=C2
InChI InChI=InChI=1S/C15H18N2O3/c1-12(13-6-4-3-5-7-13)17-11-16-10-14(17)15(18)20-9-8-19-2/h3-7,10-12H,8-9H2,1-2H3/t12-/m1/s1 Key:JJSJTELMIQBHDE-GFCCVEGCSA-N

Methoxyetomidate is an investigational anesthetic agent being developed by Jinzhou Ahon Pharmaceutical Co., Ltd. It is a short-acting intravenous anesthetic that acts as a positive allosteric modulator of GABAA receptors.^[1][2] As of 2024, methoxyetomidate is undergoing Phase 3 clinical trials for use in anesthesia.^[3][1]

1. ^ ^{a b} "ET-26 Methoxyetomidate Hydrochloride Development Information". Synapse by Patsnap. Retrieved 2024-11-23.
2. ^ Wang B, Chen S, Yang J, Yang L, Liu J, Zhang W (2017). "ET-26 hydrochloride (ET-26 HCl) has similar hemodynamic stability to that of etomidate in normal and uncontrolled hemorrhagic shock (UHS) rats". PLOS ONE. 12 (8) e0183439. Bibcode:2017PLoSO..1283439W. doi:10.1371/journal.pone.0183439. PMC 5557577. PMID 28813523.
3. ^ "ET-26 Clinical Trials Overview". Synapse by Patsnap. Retrieved 2024-11-23.

This pharmacology-related article is a stub. You can help Wikipedia by expanding it.

• v
• t
• e